Mills GB - Search Results

1

Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer.

Agarwal R, Gonzalez-Angulo AM, Myhre S, Carey M, Lee JS, Overgaard J, Alsner J, Stemke-Hale K, Lluch A, Neve RM, Kuo WL, Sorlie T, Sahin A, Valero V, Keyomarsi K, Gray JW, Borresen-Dale AL, Mills GB, Hennessy BT. Agarwal R, et al. Among authors: mills gb. Clin Cancer Res. 2009 Jun 1;15(11):3654-62. doi: 10.1158/1078-0432.CCR-08-3293. Epub 2009 May 26. Clin Cancer Res. 2009. PMID: 19470724 Free PMC article.

2

Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.

Xu FJ, Stack S, Boyer C, O'Briant K, Whitaker R, Mills GB, Yu YH, Bast RC Jr. Xu FJ, et al. Among authors: mills gb. Clin Cancer Res. 1997 Sep;3(9):1629-34. Clin Cancer Res. 1997. PMID: 9815853

3

NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas.

Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo WL, Gray JW, Siciliano M, Mills GB, Bast RC Jr. Yu Y, et al. Among authors: mills gb. Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):214-9. doi: 10.1073/pnas.96.1.214. Proc Natl Acad Sci U S A. 1999. PMID: 9874798 Free PMC article.

4

PIK3CA is implicated as an oncogene in ovarian cancer.

Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW. Shayesteh L, et al. Among authors: mills gb. Nat Genet. 1999 Jan;21(1):99-102. doi: 10.1038/5042. Nat Genet. 1999. PMID: 9916799

5

Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).

Hagopian GS, Mills GB, Khokhar AR, Bast RC Jr, Siddik ZH. Hagopian GS, et al. Among authors: mills gb. Clin Cancer Res. 1999 Mar;5(3):655-63. Clin Cancer Res. 1999. PMID: 10100719

6

The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression.

Xu F, Yu Y, Le XF, Boyer C, Mills GB, Bast RC Jr. Xu F, et al. Among authors: mills gb. Clin Cancer Res. 1999 Nov;5(11):3653-60. Clin Cancer Res. 1999. PMID: 10589783

7

Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells.

Pustilnik TB, Estrella V, Wiener JR, Mao M, Eder A, Watt MA, Bast RC Jr, Mills GB. Pustilnik TB, et al. Among authors: mills gb. Clin Cancer Res. 1999 Nov;5(11):3704-10. Clin Cancer Res. 1999. PMID: 10589790

8

Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.

Gershenson DM, Deavers M, Diaz S, Tortolero-Luna G, Miller BE, Bast RC Jr, Mills GB, Silva EG. Gershenson DM, et al. Among authors: mills gb. Clin Cancer Res. 1999 Dec;5(12):4053-8. Clin Cancer Res. 1999. PMID: 10632339

9

Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner.

Furui T, LaPushin R, Mao M, Khan H, Watt SR, Watt MA, Lu Y, Fang X, Tsutsui S, Siddik ZH, Bast RC, Mills GB. Furui T, et al. Among authors: mills gb. Clin Cancer Res. 1999 Dec;5(12):4308-18. Clin Cancer Res. 1999. PMID: 10632375

10

Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms.

Le XF, McWatters A, Wiener J, Wu JY, Mills GB, Bast RC Jr. Le XF, et al. Among authors: mills gb. Clin Cancer Res. 2000 Jan;6(1):260-70. Clin Cancer Res. 2000. PMID: 10656457

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,133 results

Search Page